When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...

Bladder cancer represents a widespread malignant neoplasm globally, characterized by a notable rate of recurrence following the initial diagnosis and treatment. Traditional methods for identifying and ...

ABSTRACT: Bladder cancer represents a widespread malignant neoplasm globally, characterized by a notable rate of recurrence following the initial diagnosis and treatment. Traditional methods for ...

Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample can effectively diagnose and stage bladder cancer, offering a much-needed ...

BLADDER CANCER is one of the most common cancers worldwide and carries high morbidity and mortality, particularly when diagnosed at an advanced stage. Early detection is critical for improving patient ...

AIxMed, a recognized innovator in AI diagnostics for urine cytology, and PathNet, a leading diagnostic laboratory, announced a strategic partnership. This collaboration aims to enhance PathNet's ...

"With its potential for screening, recurrence monitoring, treatment guidance, and prognosis prediction, utDNA is poised to transform bladder cancer management and personalize patient care." — Liang ...

Bladder cancer is mainly urothelial carcinoma, with non-muscle-invasive and muscle-invasive types, and smoking as a key risk factor. Diagnosis involves cystoscopy, biopsy, urine cytology, and imaging ...

In this phase IIb parallel cohort study, patients with BCG-unresponsive carcinoma in situ (CIS) with/without papillary disease received TAR-200 monotherapy (Cohort 2 [C2]), TAR-200 plus cetrelimab (C1 ...